BRIEF—ESSA Pharma appoints new CMO

ESSA Pharma has appointed Alessandra Cesano as chief medical officer.

Dr Cesano, formerly CMO at NanoString Technologies, will provide leadership in advancing the company's lead clinical candidate, EPI-7386 into Phase I clinical testing.

Citing her: “broad expertise in the development and clinical use of biomarkers for the more efficient development of targeted therapeutics,” chief executive David Parkinson said: “Her expertise will be instrumental in advancing the clinical development of ESSA's novel N-terminal domain inhibitor of the androgen receptor in men with prostate cancer.”